Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Identification of ACE2 as an early tissue-specific biomarker of GI-ARS using a dual specimen strategy

Award Number: R21AI193883
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/07/2025
PERIOD OF PERFORMANCE END DATE: 07/31/2027

Group Awards By:

View Award Description

Identification of ACE2 as an early tissue-specific biomarker of GI-ARS using a dual specimen strategy - Project summary/Abstract Title: Identification of ACE2 as an early tissue-specific biomarker of GI-ARS using a dual specimen strategy The project aims to develop a novel, dual-specimen biomarker strategy to improve the early detection of gastrointestinal acute radiation syndrome (GI-ARS), a critical condition that arises from ionizing radiation (IR) exposure. IR exposure can lead to both hematopoietic (H-ARS) and GI-ARS, but GI-ARS typically manifests earlier, requiring prompt diagnosis and intervention to improve survival outcomes. Existing GI-ARS biomarkers, such as serum citrulline, are effective only after the initial 48-hour window post-exposure, limiting their utility in early clinical interventions. To address this gap, this study will evaluate angiotensin-converting enzyme 2 (ACE2), an enterocyte-specific protein highly responsive to IR, as a promising early biomarker that can be detected within 1–2 days post-exposure. By combining fecal and serum measurements of ACE2, this project proposes a sensitive and minimally invasive biomarker strategy for predicting GI-ARS severity with high accuracy. This study will leverage a dual-specimen approach to provide a more comprehensive measure of GI injury, capturing both tissue-specific and systemic GI injury responses to IR. Aim 1: will evaluate the temporal dynamics and dose-dependent changes in fecal and serum ACE2 following IR exposure for early GI-ARS prediction. Using total-body irradiated (TBI) mouse models, we will monitor ACE2 levels over the critical 1 to 3.5 days post-IR period, hypothesizing that IR will induce a dose-dependent increase in fecal ACE2 (indicating enterocyte shedding) and a corresponding decrease in serum ACE2 (signaling systemic GI injury). This dual- specimen strategy is expected to yield a more precise GI-ARS prediction within the first 24–48 hours post- exposure compared to current markers. Aim 2: will evaluate the predictive value of fecal-to-serum ACE2 ratio- based biomarkers for early detection and severity of GI-ARS. Using both TBI and total abdominal irradiation (TAI) models, we will validate the fecal-to-serum ACE2 ratio's ability to reliably indicate GI-ARS severity. We will further explore whether the fecal ACE2-to-serum citrulline ratio could provide an alternative predictive metric, especially valuable for mitigating the variability often present in single biomarker models. This study introduces a dual-specimen ACE2 biomarker strategy that addresses the urgent need for early GI-ARS detection. By measuring ACE2 in both fecal and serum samples, we offer a minimally invasive approach that allows for localized (fecal) and systemic (serum) assessment of IR-induced GI injury. The fecal-to-serum ACE2 ratio may improve diagnostic accuracy, surpassing traditional biomarkers such as serum citrulline, particularly at early time points. This approach is transformative in scenarios of nuclear exposure or mass casualties, where rapid and reliable GI injury assessment is critical. The study's findings could enable swift clinical translation, enhancing survival outcomes through timely diagnosis and management of IR-induced GI injuries. 1


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $156,000 )
2026	2026	GEORGETOWN UNIVERSITY	MAIN CAMPUS	WASHINGTON	DC	20057	DISTRICT OF COLUMBIA	USA	Allergy and Infectious Diseases Research	000	2	7/3/2026	NON-COMPETING CONTINUATION	$156,000
														Subtotal = $156,000

Issue Date FY: 2025 ( Subtotal = $156,000 )
2025	2025	GEORGETOWN UNIVERSITY	MAIN CAMPUS	WASHINGTON	DC	20057	DISTRICT OF COLUMBIA	USA	Allergy and Infectious Diseases Research	000	1	8/7/2025	NEW	$156,000
														Subtotal = $156,000

Grand Total All Awards = $312,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Identification of ACE2 as an early tissue-specific biomarker of GI-ARS using a dual specimen strategy

Award Number: R21AI193883

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/07/2025

PERIOD OF PERFORMANCE END DATE: 07/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer